

## **ΠΕΤΡΟΣ Π. ΣΦΗΚΑΚΗΣ, Συνοπτικό Βιογραφικό, 12/2013**

### **ΠΑΡΟΥΣΑ ΚΑΤΑΣΤΑΣΗ:**

Καθηγητής Παθολογίας, Ιατρική Σχολή του Πανεπιστημίου Αθηνών & Διευθυντής Α΄ Προπαιδευτικής Παθολογικής Κλινικής, Λαϊκό Νοσοκομείο.

Τηλ. Α΄ΠΠΚ: 210-7771197

Τηλ. Ερευνητικού Εργαστηρίου: 210-7456461

Fax # 210-7485965

e-mail: [psfikakis@med.uoa.gr](mailto:psfikakis@med.uoa.gr)

Τηλ. 6936233816

### **ΠΡΟΠΤΥΧΙΑΚΕΣ ΣΠΟΥΔΕΣ & ΜΕΤΑΠΤΥΧΙΑΚΟΙ ΤΙΤΛΟΙ**

1973-1979: Βαρβάκειος Πρότυπος Σχολή, Απολυτήριο, (Άριστα).

1979-1985: Ιατρική Σχολή Πανεπιστημίου Αθηνών, Πτυχίο Ιατρικής, (Άριστα).

1990: Διδάκτωρ, Ιατρική Σχολή Πανεπιστημίου Αθηνών (Άριστα)

1994: Ειδικότητα Ρευματολογίας, Αθήνα,

2007: Ειδικότητα Παθολογίας, Αθήνα,

### **ΘΕΣΕΙΣ ΕΥΘΥΝΗΣ**

- 1991-1993:** Associate, Rheumatology and Clinical Immunology Services, Department of Clinical Investigation, Walter Reed AMC, Washington DC & Assistant Professor of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
- 1995-2000:** Λέκτορας του Τομέα Παθολογίας της Ιατρικής Σχολής Πανεπιστημίου Αθηνών, Α΄ Προπαιδευτική Κλινική, Λαϊκό Νοσοκομείο
- 2000- 2005** Επίκουρος Καθηγητής του Τομέα Παθολογίας της Ιατρικής Σχολής Πανεπιστημίου Αθηνών, Α΄ Προπαιδευτική Κλινική, Λαϊκό Νοσοκομείο
- 2005- 2009:** Αναπληρωτής Καθηγητής του Τομέα Παθολογίας της Ιατρικής Σχολής Πανεπιστημίου Αθηνών, Α΄ Προπαιδευτική Κλινική, Λαϊκό Νοσοκομείο
- 7/2009-σήμερα:** Καθηγητής του Τομέα Παθολογίας της Ιατρικής Σχολής Πανεπιστημίου Αθηνών, Α΄ Προπαιδευτική Κλινική, Λαϊκό Νοσοκομείο

### **ΕΠΙΣΤΗΜΟΝΙΚΕΣ ΕΤΑΙΡΕΙΕΣ**

American College of Rheumatology (ACR), International Fellow.

American Association of Immunologists (AAI), regular member.

American Federation for Clinical Research, regular member.  
Federation of American Societies of Experimental Biology (FASEB), regular member.  
American Association for the Advancement of Science, regular member.  
New York Academy of Sciences, regular member.  
International Society of Immunopharmacology, regular member.  
Clinical Immunology Society, regular member.  
Ελληνική Ρευματολογική Εταιρεία (Προέδρος ΔΣ 2010-2012)  
Ελληνική Εταιρεία Εσωτερικής Παθολογίας  
Ελληνική Εταιρεία Ανοσολογίας.

## ΕΡΕΥΝΗΤΙΚΟ ΕΡΓΟ

Έχει υψηλή διεθνή αναγνωρισιμότητα ([www.highlycitedgreekscientists.org](http://www.highlycitedgreekscientists.org)), έχει δε συμβάλλει α) στην κατανόηση της παθογένειας των αυτοάνοσων ρευματικών νοσημάτων και β) στη βελτίωση της θεραπευτικής προσεγγίσεως του Συστηματικού Ερυθηματώδους Λύκοθ, της Συστηματικής Σκληροδερμίας και της νόσου Αδαμαντιάδη- Behcet's.

**BIBΛΙΟΓΡΑΦΙΚΕΣ ΑΝΑΦΟΡΕΣ: >5.500**  
**H-INDEX=44 (GOOGLE SCHOLAR 12/2013)**

## ΔΗΜΟΣΙΕΥΣΕΙΣ

**Επιλογή 50 δημοσιεύσεων με έμφαση την τελευταία τριετία (επί συνόλου 210 σε PUBMED)**

**P.P. SFIKAKIS, M. KYRIAKIDIS, K. VERGOS, S. PAPAZOGLU, F. GEORGIAKODIS, P. TOUTOUZAS, P. SFIKAKIS:** Diffusing capacity of the lung and nifedipine in Systemic Sclerosis.  
*Arthritis and Rheumatism* 1990; 33: 1634-1639

**P.P. SFIKAKIS, M. KYRIAKIDIS, K. VERGOS, G. VYSSOULIS, T. PSARROS, C.KYRIAKIDIS, M. MAVRIKAKIS, P. SFIKAKIS, P. TOUTOUZAS:** Cardiopulmonary hemodynamics in Systemic Sclerosis and response to nifedipine and captopril.  
*American Journal of Medicine* 1991; 90: 539-546.

**P.P. SFIKAKIS, B.K. McCUNE, M. TSOKOS, K. ARONI, G. VAIPOULOS, G.C. TSOKOS:** Immunohistological demonstration of transforming growth factor beta (TGF-b) isoform expression in the skin of patients with Systemic Sclerosis.  
*Clinical Immunology Immunopathology* 1993; 69: 199-204.

**P.P. SFIKAKIS, J. TESAR, S. THEOCHARIS, G.L. KLIPPLE, G.C. TSOKOS:** Increased frequency of *in vivo* hprt gene-mutated T cell in the peripheral blood of patients with Systemic Sclerosis.  
*Annals of the Rheumatic Diseases* 1994; 53:122-127.

**P.P. SFIKAKIS, R. OGLESBY, P. SFIKAKIS, G.C. TSOKOS:** B7/BB1 provides an important costimulatory signal for CD3-mediated T lymphocyte proliferation in patients with Systemic Lupus Erythematosus.

*Clinical Experimental Immunology* 1994; 96: 8-13.

**P.P. SFIKAKIS, E. ZOGRAFOU, V. VIGLIS, I. PISKONDAKI, A. INIOTAKI, G.C. TSOKOS, P. SFIKAKIS, E. CHOREMI:** CD28 expression on T cell subsets in vivo and CD28-mediated T cell response in vitro in patients with rheumatoid arthritis.

*Arthritis and Rheumatism* 1995; 38: 649-654.

**P.P. SFIKAKIS, V. SOULIOTIS, A. N. AKBAR, N. KATSILAMBROS, V. A. HOFFBRAND, P. PANAYIOTIDIS.** Regulation of bcl-2 and fas expression in primary activation of human peripheral lymphocytes is not sensitive to dexamethasone or cyclosporin-A.

*Human Immunology.* 1996; 50: 121-126.

**P.P. SFIKAKIS, D.D. MITSIKOSTAS, M.N. MANOUSSAKIS, D. FOUKANELI, H.M. MOUTSOPOULOS.** Headache in systemic lupus erythematosus: A controlled study.

*British Journal of Rheumatology* 1998; 37: 300-303.

**MITSIKOSTAS DD, SFIKAKIS PP, GOADSBY PJ.**

A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth.

*Brain:* 2004; 127:1200-1209.

**SFIKAKIS PP, THEODOSSIADES PG, KATSIARI CG, KAKLAMANIS P, MARKOMICHELAKIS NN.** Effect of Infliximab in sight-threatening panuveitis in Behcet's disease.

*The Lancet,* 2001, 358:295-296

**SFIKAKIS PP, KAKLAMANIS P, THEODOSSIADES PG, ELEZOGLU A, EFTHIMIOU S, KATSILAMBROS N, MARKOMICHELAKIS NN.**

Infliximab for recurrent sight-threatening ocular inflammation in Adamantiades -Behcet's disease.

*Annals of Internal Medicine* 2004; 140:404-406

**LIOSSIS SN, SOLOMOU EE, DIMOPOULOS MA, PANAYIOTIDIS P, M. MAVRIKAKIS, SFIKAKIS PP.**

B-cell kinase Lyn deficiency in patients with Systemic Lupus Erythematosus

*Journal of Investigative Medicine,* 2001, 49:157-165.

**KATSIARI CG, LIOSSIS SN, SOULIOTIS V, MANNOUSSAKIS MN, DIMOPOULOS MA, SFIKAKIS PP:**

Aberrant expression of the costimulatory molecule CD40-Ligand in monocytes from patients with Systemic Lupus Erythematosus

*Clinical Immunology* 2002, 103: 54-62

**KATSIARI CG, LIOSSIS SN, DIMOPOULOS MA, CHARALAMBOPOULOS DV, MAVRIKAKIS M, SFIKAKIS PP.**

CD40L overexpression on T cells and monocytes from patients with Systemic Lupus Erythematosus is resistant to calcineurin inhibition.

*Lupus* 2002, 11:370

MAVRIKAKIS I, **SFIKAKIS PP**, MAVRIKAKIS E, ROUGAS K, NIKOLAOU A, KOSTOPOULOS C, MAVRIKAKIS M.

The incidence of irreversible retinal toxicity in patients treated with Hydroxychloroquine. A reappraisal.

*Ophthalmology* 2003, 110:1321-1326

**SFIKAKIS PP**, MARKOMICHELAKIS N., THEODOSSIADIS GP, GRIGOROPOULOS V, KATSILAMBROS N, THEODOSSIADIS GP

Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-TNF monoclonal antibody Infliximab.

*Diabetes Care* 2005; 28: 445-447

MOYSSAKIS I, GIALAFOS E, VASSILIOU V, TAKTIKOU E, KATSIARI C, PAPAPOPOULOS D, **SFIKAKIS PP**.

Aortic stiffness in Systemic Sclerosis is increased independently of the extent of skin involvement.

*Rheumatology* 2005; 44:251-254

MARKOMICHELAKIS N, THEODOSSIADIS PG, **SFIKAKIS PP**.

Regression of choroidal neovascularization secondary to age-related macular degeneration following Infliximab therapy.

*American Journal of Ophthalmology*, 2005; 139:537-540

**SFIKAKIS PP**, BOLETIS JN, LIONAKI SN, VIGKLIS G, FRAGIADAKI KG, INIOTAKI A, MOUTSOPOULOS HM. Remission of proliferative lupus nephritis following anti-B cell therapy is preceded by downregulation of the T cell costimulatory molecule CD40-ligand.

*Arthritis and Rheumatism* 2005; 52; 501-513

**SFIKAKIS PP**, ILIOPOULOS A, ELEZOGLU A, KITTAS C, STRATIGOS A.

Psoriasis induced by anti-TNF therapy: A paradoxical adverse reaction

*Arthritis and Rheumatism*, 2005; 52:2513-2518

**SFIKAKIS PP**, GOURGOULIS GM, MOULOPOULOS LA, KOUVATSEAS G, THEOFILOPOULOS AN, DIMOPOULOS MA.

Age-related thymic activity in adults following chemotherapy-induced lymphopenia

*European Journal of Clinical Investigation*, 2005; 35:380-387

SOULIOTIS V, DIMOPOULOS MA, **SFIKAKIS PP**.

Gene-specific Formation and Repair of DNA Monoadducts and Interstrand Crosslinks after Therapeutic Exposure to Nitrogen Mustards

*Clinical Cancer Research* 2003 , 9: 4465-4474

DIMOPOULOS MA, SOULIOTIS V, ANAGNOSTOPOULOS A, PAPADIMITRIOU C, **SFIKAKIS PP**.

The extent of damage and repair in the p53 tumor suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem cell transplantation is individualized and may predict clinical outcome.

*Journal of Clinical Oncology* 2005; 23:4381-4389

**SFIKAKIS PP**, PAPAMICHAEL C, STAMATELOPOULOS KS, TOUSOULIS D, FRAGIADAKI KG, KATSICHTI P, STEFANADIS C, MAVRIKAKIS M. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. *Arthritis Rheumatism* 2007; 56:1985-1993.

DIMOPOULOS MA, SOULIOTIS VL, ANAGNOSTOPOULOS A, BAMIA C, POULI A, BALTADAKIS I, TERPOS E, KYRTOPOULOS SA, **SFIKAKIS PP**. Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. *Haematologica*. 2007; 92:1505-1512.

POULOPOULOU C, PAPADOPOULOU-DAIFOTI Z, HATZIMANOLIS A, FRAGIADAKI K, POLISSIDIS A, ANDERZANOVA E, DAVAKI P, KATSIARI CG, **SFIKAKIS PP**. Glutamate levels and activity of the T-cell voltage-gated potassium Kv1.3 channel in patients with systemic lupus erythematosus. *Arthritis Rheumatism* 2008; 58:1445-1450

BAMIAS G, SIAKAVELLAS S, STAMATELOPOULOS K, CHRYSOCHOOU E, PAPAMICHAEL C, **SFIKAKIS PP**. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. *Clinical Immunology* 2008; 129: 249-255

KARANIKOLAS G, CHARALAMBOPOULOS VAYIOPOULOS G, ANDRIANAKOS A, RAPTI A, KARRAS D, KSKANI, E, **SFIKAKIS PP**. Adjunctive Anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporine-A monotherapy: A 48-week, comparative, prospective study. *Rheumatology* 2008, 47: 1384-1388

STAMATELOPOULOS KS, KITAS GD, PAPAMICHAEL CM, CHRYSOCHOOU E, KYRKOU K, GEORGIOPOULOS G, PROTOGEROU A, PANOULAS VF, SANDOO A, TENTOLOURIS N, MAVRIKAKIS M, **SFIKAKIS PP**. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. *Arterioscler Thromb Vasc Biol*. 2009 Oct;29(10):1702-8.

STAMATELOPOULOS KS, KITAS GD, PAPAMICHAEL CM, KYRKOU K, ZAMPELI E, FRAGIADAKI K, PANOULAS VF, MAVRIKAKIS M, **SFIKAKIS PP**. Subclinical peripheral arterial disease in rheumatoid arthritis. *Atherosclerosis*. 2010 Sep;212(1):305-9.

**SFIKAKIS PP**, GRIGOROPOULOS V, EMFIETZOGLOU I, THEODOSSIADIS G, TENTOLOURIS N, DELICHA E, KATSIARI C, ALEXIADOU K, HATZIAGELAKI E, THEODOSSIADIS PG. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. *Diabetes Care*. 2010 Jul;33(7):1523-8.

ARIDA A, KYPRIANOU M, KANAKIS M, **SFIKAKIS PP**. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis.

*BMC Musculoskelet Disord.* 2010 Mar 8;11:44.

**SFIKAKIS PP**. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.

*Curr Dir Autoimmun.* 2010;11:180-210.

ARIDA A, FRAGIADAKI K, GIAVRI E, **SFIKAKIS PP**. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients.

*Semin Arthritis Rheum.* 2011 Aug;41(1):61-70.

MARKOMICHELAKIS N, DELICHA E, MASSELOS S, FRAGIADAKI K, KAKLAMANIS P, **SFIKAKIS PP**.

A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.

*Rheumatology (Oxford).* 2011 Mar;50(3):593-7.

KATSIARI CG, GIAVRI I, MITSIKOSTAS DD, YIANNOPOULOU KG, **SFIKAKIS PP**. Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation.

*Eur J Neurol.* 2011 Apr;18(4):556-63

BAMIAS G, EVANGELOU K, VERGOU T, TSIMARATOU K, KAL TSA G, ANTONIOU C, KOTSINAS A, KIM S, GORGOLIS V, STRATIGOS AJ, **SFIKAKIS PP**.

Upregulation and nuclear localization of TNF-like cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions.

*Exp Dermatol.* 2011 Sep;20(9):725-31

KARANIKOLAS GN, KOUKLI EM, KATSALIRA A, ARIDA A, PETROU D, KOMNINO E, FRAGIADAKI K, ZACHARIOUDAKI A, LASITHIOTAKIS I, GIAVRI E, VAIOPOULOS G, **SFIKAKIS PP**. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.

*J Rheumatol.* 2011 Nov;38(11):2466-74.

MITSIKOSTAS DD, CHALARAKIS NG, MANTONAKIS LI, DELICHA EM, **SFIKAKIS PP**. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice.

*Eur J Neurol.* 2012 May;19(5):672-80

**SFIKAKIS PP**, TSOKOS GC. Towards the next generation of anti-TNF drugs.

*Clin Immunol.* 2011 Dec;141(3):231-5

MARKOMICHELAKIS N, DELICHA E, MASSELOS S, **SFIKAKIS PP**. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients.

*Am J Ophthalmol.* 2012 Sep;154(3):534-541.

PROTOGEROU A, ZAMPELI E, TENTOLOURIS N, MAKRILAKIS K, KITAS G, **SFIKAKIS PP**. Subclinical femoral atheromatosis in rheumatoid arthritis: comparable prevalence to diabetes mellitus in a case-control study.  
*Ann Rheum Dis. 2012 Sep;71(9):1534-6.*

ZAMPELI E, PROTOGEROU A, STAMATELOPOULOS K, FRAGIADAKI K, KATSIARI CG, KYRKOU K, PAPAMICHAEL CM, MAVRIKAKIS M, NIGHTINGALE P, KITAS GD, **SFIKAKIS PP**. Predictors of new atherosclerotic carotid plaque development in patients with rheumatoid arthritis: a longitudinal study. .  
*Arthritis Res Ther. 2012 Mar 5;14(2):R44*

STAMATELOPOULOS KS, GEORGIPOULOS G, PAPAIOANNOU T, LAMBRINOUDAKI I, KOUZOUPIS A, VLACHOPOULOS C, GEORGIIOU SP, MANIOS E, ALEVIZAKI M, PAPAMICHAEL CM, **SFIKAKIS PP**.  
Can premenstrual syndrome affect arterial stiffness or blood pressure?  
*Atherosclerosis. 2012 Sep;224(1):170-6.*

PANOPOULOS ST, BOURNIA VK, **SFIKAKIS PP** Is vasculopathy associated with systemic sclerosis more severe in men? .  
*J Rheumatol. 2013 Jan;40(1):46-51.*

ZAMPELI E, RAFTAKIS I, MICHELONGONA A, NIKOLAOU C, ELEZOGLU A, TOUTOUZAS K, SIORES E, **SFIKAKIS PP**. Detection of subclinical synovial inflammation by microwave radiometry.  
*PLoS One. 2013 May 31;8(5):e64606*

BAMIAS G, STAMATELOPOULOS K, ZAMPELI E, PROTOGEROU A, SIGALA F, PAPAMICHAEL C, CHRISTOPOULOS P, KITAS GD, **SFIKAKIS PP** Circulating levels of TNF-like cytokine 1A correlate with the progression of atheromatous lesions in patients with rheumatoid arthritis. .  
*Clin Immunol. 2013 May;147(2):144-50.*

PANOPOULOS ST, BOURNIA VK, TRAKADA G, GIAVRI I, KOSTOPOULOS C, **SFIKAKIS PP**. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study.  
*Lung. 2013 Oct;191(5):483-9*

PROTOGEROU AD, PANAGIOTAKOS DB, ZAMPELI E, ARGYRIS AA, ARIDA K, KONSTANTONIS GD, PITSAVOS C, KITAS GD, **SFIKAKIS PP**. Arterial hypertension assessed "out-of-office" in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated "white coat" phenomenon.  
*Arthritis Res Ther. 2013 Oct 2;15(5):R142.*

KALRA S, SILMAN A, AKMAN-DEMIR G, BOHLEGA S, BORHANI-HAGHIGHI A, CONSTANTINESCU CS, HOUMAN H, MAHR A, SALVARANI C, **SFIKAKIS PP**, SIVA A, AL-ARAJI A. Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations.  
*J Neurol. 2013 Dec 24. [Epub ahead of print]*